GLP-1s: The questions health systems should be asking

Thursday, August 1st, 2024 | 12:00 PM - 1:00 PM CT

The blockbuster drug class of GLP-1s prompts big questions for how obesity and its related conditions affect health systems. Since gaining popularity in 2020, drugs like Ozempic, Mounjaro, Wegovy and Trulicity have unleashed unknowns for both the near and long term, including the drugs' effects on patient volumes, questions around cost and coverage, and shifting health needs or patient expectations. 

After serving as president and CEO of Philadelphia-based Jefferson Health for eight years, Stephen Klasko, MD, has spent a great deal of time and energy on GLP-1 strategy and effects in his role as a special advisor to General Catalyst. In this editorial webinar, Becker's Healthcare's Molly Gamble sits down with Dr. Klasko to separate signal from noise and focus on the most important issues regarding weight loss drugs that health systems should focus on in the next 18 months. 

Topics include:
  • Health system preparedness for the impacts of game-changing drugs
  • GLP-1s' ties and disconnects with health equity
  • Long-term consequences of GLP-1s
  • New systemic needs triggered by GLP-1 availability and use 

Register now to be part of the conversation.

Presenters:

Molly Gamble headshot - Emma Goodman

Molly Gamble

Vice President of Editorial, Becker's Healthcare

Stephen Klasko - Emma Goodman

Stephen Klasko, MD

Former President and CEO, Jefferson University & Jefferson Health